University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "Breast"



Treatment trials which apply specifically to your search:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-15-2

Trial Leaders:
Jorge Nieva

STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-15-5

Trial Leaders:
Anthony El-Khoueiry

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

Treatment:
Chemotherapy: Systemic

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-15

Trial Leaders:
Anthony El-Khoueiry

A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
David Quinn

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-14-3

Trial Leaders:
Syma Iqbal

Phase II Study of Single Agent Regorafenib in Patients with Advanced/Metastatic Neuroendocrine Tumors

Treatment:
Chemotherapy: Systemic

0S-16-14

Trial Leaders:
David Quinn

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4

Treatment:
Biological Response Modifier

0S-17-3

Trial Leaders:
Julie Lang

Phase 2a Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases

Treatment:
Chemotherapy: Local

0S-17-5

Trial Leaders:
Christina M. Dieli-Conwright

Circuit, interval-based Aerobic and Resistance Exercise to Target Metabolic Dysregulation: The CARE Study for Breast and Prostate Cancer Survivors

Treatment:
Other

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-13-1

Trial Leaders:
Min Janice Lu

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-14-5

Trial Leaders:
Christina M. Dieli-Conwright

High-intensity Interval training (HIT) for Breast Cancer Patients during Trastuzumab or Anthracycline Use

Treatment:
Other

1B-16-8

Trial Leaders:
Min Janice Lu

Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)

Treatment:
Hormone
Other

1B-17-7

Trial Leaders:
Julie Lang

A large scale multicenter phase 2 study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Treatment:
Hormone

7H-16-1

Trial Leaders:
Jorge Nieva

A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy

CTSU-A211102

Trial Leaders:
Julie Lang

Testing for Atypia in Random Periareolar Fine Needle Aspiration (Rpfna) Cytology after 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women

Treatment:
Other

CTSU-A221505

Trial Leaders:
Naomi Schechter

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Treatment:
Radiation: External

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

ctsu/CALGB-A011202

Trial Leaders:
Julie Lang

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

CTSU/NRG-BR002

Trial Leaders:
Jason Ye

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Hormone
Radiation: External
Surgery

CTSU/NRG-BR003

Trial Leaders:
Min Janice Lu

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Treatment:
Chemotherapy: Systemic

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Naomi Schechter

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/NSABP-B-55

Trial Leaders:
Min Janice Lu

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Treatment:
Other

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1418-BR006

Trial Leaders:
Min Janice Lu

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

Treatment:
(No treatments specified)

Phase I trials for all solid tumors:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-7

Trial Leaders:
Anthony El-Khoueiry

An Open-label, Dose-finding and Proof of Concept Study for Probody™ therapeutics (probody tx) in Subjects with Metastatic or Locally Advanced Unresectable Solid Tumors and/or Lymphomas

Treatment:
Immunotherapy
Other

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-14

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Treatment:
Chemotherapy: Systemic

0C-17-15

Trial Leaders:
Anthony El-Khoueiry

A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-17-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies

Treatment:
Biological Response Modifier

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-16-14

Trial Leaders:
David Quinn

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4

Treatment:
Biological Response Modifier

7H-16-1

Trial Leaders:
Jorge Nieva

A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-3

Trial Leaders:
Peter Conti

18F-FMAU for Imaging in Cancer Patients.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-15

Trial Leaders:
Patrick Williams

Are Last Impressions Lasting Impressions? Intervention of Ringing a Bell at the End of Cancer Treatment


0S-15-16

Trial Leaders:
Akil Merchant

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-15-17

Trial Leaders:
Patrick Williams

Patient Perceptions of Side Effects of Cancer Chemoradiotherapy


0S-16-9

Trial Leaders:
Ebrahim Zandi

The Role of Microbiome in Cancer Therapy


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-16-3

Trial Leaders:
Mary W. Yamashita

Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography with Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography with or without Targeted Ultrasound


1B-16-4

Trial Leaders:
Linda Hovanessian

A Prospective Validation Study Of A Rapid Point-Of-Care Breath Test For Breast Cancer


1B-16-5

Trial Leaders:
Stephen Gruber

Trial of Strategies to Communicate Genetic Information to Different Ethnic and Racial Subpopulations


1B-16-7

Trial Leaders:
Min Janice Lu

Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer


1B-17-1

Trial Leaders:
Julie Lang

Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology


1B-17-8

Trial Leaders:
Julie Lang

Harvest of Circulating Tumor Cells (CTCs) from Patients with Metastatic Breast Cancer (MBC) using the ParsortixTM PC1 System.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


CTSU/NRG-BR005

Trial Leaders:
Julie Lang

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery